JCR Pharmaceuticals Co., Ltd. (4552.T)

JPY 610.0

(-0.81%)

Market Cap (In JPY)

76.55 Billion

Revenue (In JPY)

42.87 Billion

Net Income (In JPY)

5.5 Billion

Avg. Volume

511.13 Thousand

Currency
JPY
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
466.0-1228.0
PE
-
EPS
-
Beta Value
0.027
ISIN
JP3701000006
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Mr. Shin Ashida
Employee Count
-
Website
https://www.jcrpharm.co.jp
Ipo Date
2005-11-17
Details
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.